Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 4: Short-term Objective B  

$23,229,501.04
Fiscal Year: 2010

Green dot: Objective has greater than or equal to the recommended funding.4SB. Standardize and validate at least 20 model systems (e.g., cellular and/or animal) that replicate features of ASD and will allow identification of specific molecular targets or neural circuits amenable to existing or new interventions by 2012. IACC Recommended Budget: $75,000,000 over 5 years.

Download 2010 Question 4: Short-term Objective B projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Neural and cognitive mechanisms of autism Sur, Mriganka Massachusetts Institute of Technology
Neural mechanisms of social cognition and bonding Young, Larry Emory University
Neural mechanisms of social cognition and bonding Young, Larry Emory University
Neurobiological mechanism of 15q11-13 duplication autism spectrum disorder Anderson, Matthew Beth Israel Deaconess Medical Center
Neurobiology of mouse models for human chr 16p11.2 microdeletion and fragile X Bear, Mark Massachusetts Institute of Technology
Neurobiology of sociability in a mouse model system relevant to autism Brodkin, Edward University of Pennsylvania
Neurogenetic model of social behavior heterogeneity in autism spectrum disorders Platt, Michael Duke University
Neurogenomics in a model for procedural learning Hilliard, Austin University of California, Los Angeles
Neuroligin function in vivo: Implications for autism and mental retardation Powell, Craig University of Texas Southwestern Medical Center
Neuropharmacology of motivation and reinforcement in mouse models of autistic spectrum disorders Malanga, C.J. University of North Carolina School of Medicine
Novel genetic animal models of autism Powell, Craig University of Texas Southwestern Medical Center
Novel models to define the genetic basis of autism Mills, Alea Cold Spring Harbor Laboratory
Novel probiotic therapies for autism Patterson, Paul California Institute of Technology
Novel strategies to manipulate Ube3a expression for the treatment of autism and Angelman syndrome Roth, Bryan University of North Carolina at Chapel Hill
NrCAM, a candidate susceptibility gene for visual processing deficits in autism Maness, Patricia University of North Carolina at Chapel Hill
Optimization of methods for production of both ICSI- and SCNT derived baboon embryonic stem cells Schatten, Gerald Southwest Foundation For Biomedical Research
Patient iPS cells with copy number variations to model neuropsychiatric disorders Ellis, James The Hospital for Sick Children
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes Pedersen, Cort University of North Carolina at Chapel Hill
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes Jarstfer, Michael University of North Carolina at Chapel Hill
Preclinical testing of novel oxytocin receptor activators in models of autism phenotypes Moy, Sheryl University of North Carolina at Chapel Hill
Regulation of gene expression in the brain Young, Walter National Institutes of Health
Role of a novel Wnt pathway in autism spectrum disorders Reichardt, Louis University of California, San Francisco
Role of L-type calcium channels in hippocampal neuronal network activity Owen, Scott Stanford University
Role of UBE3A in neocortical plasticity and function Ehlers, Michael Duke University
Serotonin, autism, and investigating cell types for CNS disorders Dougherty, Joseph The Rockefeller University